Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank

May 14, 2024 4:12 PM EDT

Deutsche Bank analyst James Shin lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $10.00 (from $12.00) while maintaining a Buy rating.

The analyst comments "We're updating our STRO model for 1Q24 results, maintaining our Buy rating and lowering our price target to... More

Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)

May 14, 2024 8:25 AM EDT

Wedbush analyst David Nierengarten reiterated an Outperform rating and $8.00 price target on Sutro Biopharma (NASDAQ: STRO)

The analyst comments "STRO reported 1Q24 earnings. The company continues to advance lead asset luvelta (FolR-targeted ADC) through multiple clinical studies. Part 1 of the registration-directed REFRaME-01 study in... More